Shanghai Pharmaceuticals
Shanghai Pharmaceuticals is a distribution giant that bought its way to the top — not a drug developer that earned it.
Photography
The medium that changed what everything else was for.
- 15
- in business
- 10:37
- average
- 159 min
- in total
- 37
- across the network
All briefs
AbbVie
AbbVie didn’t win the autoimmune market with science — it won with patents, pricing, and settlements.
AstraZeneca
AstraZeneca is not a British company — it is a 1999 merger with no disclosed financials, no stated cost model, and no evidence of how it actually delivers value beyond its own description.
Aurobindo Pharma
Aurobindo Pharma doesn’t sell cures—it sells compliance at scale.
Cipla
Cipla built scale before science—and still runs on that engine.
Daiichi Sankyo
A merger-born giant that bought its way into oncology — but still answers to US prosecutors for kickbacks.
Dr. Reddy's Laboratories
K. Anji Reddy · 1984
Dr. Reddy's Laboratories is a business case in disciplined vertical progression: API → branded formulation → export credential → finished product. Its early wins were tactical, not structural. No data on scale, margins, or longevity is provided — only sequence, timing, and pricing intent.
Eisai (company)
Eisai didn’t build a global pharma business — it bought one, piece by piece, while outsourcing its biggest launches.
Lupin (company)
Lupin built its business on public health contracts — not disruption, not patents, not venture capital.
Novo Nordisk
Novo Nordisk is not a biotech disruptor — it is the institutional heir to Denmark’s 1920s insulin labs, built on merger, not molecule.
Sinopharm (company)
A state-owned vaccine developer that delivered peer-reviewed efficacy — and sold 400,520 faulty doses.
Sun Pharma
Sun Pharma proves that global scale in generics isn’t built on patents or pipelines — it’s built on factories, filings, and foot soldiers in FDA, EMA and CDSCO exam rooms.
Kodak
George Eastman · 1880
Kodak was not a camera company first — it was a film company that used cameras to distribute its consumable. Its 1888 system created a new market by removing technical barriers. Its dominance came from controlling the film supply chain, not the hardware. No source mentions digital disruption, so the brief stops at peak film-era success.
Novartis
A merger born of necessity, not vision — Novartis was built to survive, not invent.
Roche
Roche isn’t a biotech pioneer — it’s a precision acquirer that turns diagnostics and drugs into a single revenue stream.